The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals ComparedWith Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily A 26-week, randomized, open-label, parallel-group, treat-to-target trial in people with type 2 diabetes

RESEARCH DESIGN ANDMETHODSdThis 26-week, open-label, treat-to-target trial enrolled adults ($18 years) with type 2 diabetes who were either insulin-naïve and receiving oral antidiabetic drugs (OADs) (HbA1c = 7–11%) or previously on basal insulin6OAD(s) (HbA1c = 7–10%). Participants were randomized to 1) once-daily IDeg in a prespecified dosing schedule, creating 8–40-h intervals between injections (IDeg OD Flex; n = 229); 2) once-daily IDeg at the main evening meal (IDegOD; n = 228); or 3) once-daily insulin glargine at the same time each day (IGlarOD; n = 230). The primary outcome was noninferiority of IDeg OD Flex to IGlar OD in HbA1c reduction after 26 weeks.